Concepedia

Daniel Li

DL

43

Publications

5.9K

Citations

25

H-Index

1995

Active since

Affiliations

The Ohio State University(Current)

Cornell University

Fred Hutch Cancer Center

University of Washington

Harvard University

Daniel Li is an author at The Ohio State University specializing in medicine, immunology, and immunotherapy.

ORCID

Top concepts

Publications per year

1995–2024

43

Publications

43

Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

Richard R. Furman, Jeff P. Sharman, Steven Coutré et al. · New England Journal of Medicine · 2014 · 1.7K citations · Full text

PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma

Ajay K. Gopal, Brad S. Kahl, Sven de Vos et al. · New England Journal of Medicine · 2014 · 1K citations · Full text

Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of Ibrutinib

Cameron J. Turtle, Kevin A. Hay, Laïla‐Aïcha Hanafi et al. · Journal of Clinical Oncology · 2017 · 649 citations

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia

Jennifer R. Brown, John C. Byrd, Steven Coutré et al. · Blood · 2014 · 583 citations · Full text

Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy

Kevin A. Hay, Jordan Gauthier, Alexandre V. Hirayama et al. · Blood · 2019 · 389 citations · Full text

Rows per page

1–5 of 43